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The incidence of drug-induced congestive heart failure with 
several newer antiarrhythmic agents including encainide, 
ethmozine, lorcainide, mexiletine, propafenone and tocain- 
ide was determined in a group of 407 patients who under- 
went 1,133 drug tests. The incidence rate ranged from 
0.7% with lorcainide to 4.7% with propafenone. Conges- 
tive heart failure was present in 167 patients (41%) who 
underwent 491 drug trials. Congestive failure was induced 
in 15 (9%) of these 167 patients and involved 19 (3.9%) of 
Ever larger numbers of patients are being resuscitated from 
sudden cardiac arrest and identified as having ventricular 
tachycardia. The major therapeutic intervention for prophy- 
laxis involves the use of antiarrhythmic drugs (l-3). A 
majority of these patients have significant left ventricular 
dysfunction. Additionally, many patients with severely de- 
pressed left ventricular function and congestive heart failure 
have frequent complex ventricular arrhythmias (4-6) that 
may be harbingers of sudden death and for which antiar- 
rhythmic drugs are prescribed. However, antiarrhythmic 
drugs exert negative inotropic effects, with the potential of 
precipitating or aggravating congestive heart failure (7,8). 
The purpose of this retrospective study was to determine 
the incidence of aggravation or provocation of congestive 
failure by antiarrhythmic drugs in a large group of patients 
with serious ventricular arrhythmias. The six drugs evalu- 
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the 491 tests. Left ventricular ejection fraction was 20 A 
8% in patients who developed congestive failure, in con- 
trast to 39 f 19% in those who did not (p < 0.001). 
It is concluded that each of the six antiarrhythmic drugs 
examined has the potential to aggravate congestive heart 
failure in patients with reduced left ventricular ejection 
fraction or a history of congestive heart failure, but the 
incidence rate is low and its occurrence unpredictable. 
(J Am Co11 Cardiol1989;14:1326-30) 
ated were the newer antiarrhythmic agents mexiletine, 
tocainide, ethmozine, lorcainide, encainide and pro- 
pafenone. An additional objective was to identify, if possi- 
ble, the risk factors for drug-induced congestive heart fail- 
ure. 
Methods 
Study patients (Table 1). Data were collected by review- 
ing hospital and arrhythmia clinic records. The clinic had a 
close follow-up of all patients evaluated for arrhythmias, and 
recorded any symptom or finding. Patients were instructed 
to report to the clinic any change in their symptoms, and all 
patients were telephoned within 1 month of discharge from 
the hospital. 
The study group consisted of 407 patients (303 male and 
104 female), with a mean age of 56 years (range 15 to 83), 
representing all patients referred for therapy of recurrent 
ventricular tachyarrhythmias during a 6 year period. In each 
patient, conventional antiarrhythmic drugs including quini- 
dine, disopyramide, procainamide and a beta-adrenergic 
blocking agent were not effective or poorly tolerated. The 
majority of patients (62%) had coronary artery disease; the 
remaining patients had valvular heart disease (lo%), cardio- 
myopathy (8%) or other cardiac conditions (20%). The 
presenting arrhythmia was ventricular fibrillation in 26% of 
patients, sustained ventricular tachycardia in 42% and non- 
sustained ventricular tachycardia in 26%; the remaining 6% 
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Table 1. Clinical Characteristics of the Study Group 
No. of patients 
No. (%) male 




No. (%) with cardiac diagnoses 









No. (%) with history of CHF 















38 + I9 
CHF = congestive heart failure; LVEF = left ventricular ejection 
fraction: VF = ventricular fibrillation: VPBs = ventricular premature com- 
pheres; VT = ventricular tachycardia. 
of patients had symptomatic and frequent ventricular pre- 
mature beats. A history of congestive failure was present in 
167 patients (41%). Clinically significant congestive heart 
failure was diagnosed if the patient had a history of typical 
symptoms and physical findings in association with a chest 
X-ray study consistent with heart failure. 
Drug evaluation protocol. The determination of the ef- 
fects of drugs on arrhythmias involved four phases of study, 
which have been described previously (3,9). After patients 
were admitted to the hospital, antiarrhythmic drugs were 
discontinued. Digitalis, diuretic drugs, beta-blockers, va- 
sodilators and calcium channel blocking agents were contin- 
ued if clinically indicated for treatment of heart failure or 
angina. Patients with overt congestive heart failure were 
treated until compensated, and their condition had to have 
been stable for at least 1 week before they entered the 
protocol for evaluating antiarrhythmic drugs. During the 
control period of observation, patients were in stable condi- 
tion and free of congestive heart failure for at least 10 to 12 
days before antiarrhythmic drugs were administered. Phase 
0 began after a drug-free period of at least four half-lives of 
the prior antiarrhythmic drug. During this phase, patients 
underwent control studies that included 48 h of ambulatory 
electrocardiographic (ECG) monitoring and symptom- 
limited exercise testing on a motorized treadmill. Baseline 
left ventricular function was assessed by radionuclide ven- 
triculography with the use of gated blood pool scanning in 
232 (57%) of the 407 patients. This group included 109 of the 
167 patients with a history of congestive heart failure. 
At the conclusion of control studies, drugs were evalu- 
ated by previously described invasive or noninvasive tech- 
niques (9,lO). Phase 1 investigations involved acute drug 
testing. After a 30 min control period, a single large dose of 
drug was administered orally and ECG monitoring by 
trendscription continued for 3 h. At the completion of a 
series of acute drug tests, those drugs determined to be of 
benefit were evaluated during a short period of maintenance 
therapy (phase 2). Drugs possessing active metabolites or 
those with a long accumulation time (for example, encainide 
or lorcainide) were not tested acutely, but only during 
short-term maintenance therapy. During phase 2, which 
lasted for 48 to 96 h, the dose of drug was titrated to its effect 
on arrhythmia or the occurrence of side effects. At the 
completion of this period, response to the antiarrhythmic 
drug was assessed by repeat ambulatory ECG monitoring 
and exercise testing. Long-term maintenance therapy with a 
selected drug was defined as phase 3. 
Patients with a low density of spontaneously occurring 
ventricular arrhythmias or those who demonstrated signifi- 
cant day to day variability in ventricular arrhythmia fre- 
quency underwent electrophysiologic study to assess drug 
efficacy. The protocol for electrophysiologic study has been 
previously described (10). Drug evaluation involved both 
acute testing and maintenance therapy. 
An effective response, as determined with both ECG 
monitoring and exercise testing, was defined as (9): 1) total 
elimination of runs of nonsustained ventricular tachycardia; 
2) reduction of couplets by ~90%; and 3) >50% reduction in 
ventricular premature beats. When drug selection was 
guided by electrophysiologic testing, the criterion for ef- 
ficacy was the inability to induce three or more repetitive 
ventricular premature beats when up to three extrastimuli 
were added during ventricular pacing at cycle lengths of 600 
and 500 ms (10). If the antiarrhythmic drug was effective and 
well tolerated. the patient continued to take it as part of a 
long-term treatment program (phase 3). 
Drugs evaluated. The newer antiarrhythmic drugs evalu- 
ated were those administered to and evaluated in 2100 
patients and included encainide, ethmozine, lorcainide, mex- 
iletine, propafenone and tocainide. Flecainide was not eval- 
uated because experience with this agent was limited during 
this period of time. No patient was excluded from treatment 
with a particular drug on the basis of left ventricular ejection 
fraction or a history of congestive heart failure. Table 2 lists 
the doses of each drug administered. There were a total of 
1,133 drug studies; 246 (22%) were acute drug tests and 887 
(78%) involved short-term maintenance. In each case, acute 
drug testing was followed by a short period of maintenance 
therapy unless side effects occurred. Noninvasive tech- 
niques were used in 895 drug studies (79%), and 238 studies 
(21%) involved electrophysiologic testing. The 167 patients 
with a history of congestive heart failure underwent 491 
antiarrhythmic drug trials (2.9ipatient); the 240 patients 
without heart failure underwent 642 drug studies (2.71 
patient) (p = NS). 
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Table 2. Incidence of Congestive Heart Failure Induction After Antiarrhythmic Drug Administration 
No. of Cases 
Dose (mg) No. of No. of of CHF 
Inductions Patients With Worsening in 
No. of Acute Drug Daily of CHF a History of the CHF 
Drug Drug Tests Testing Maintenance (%) CHF (%) Group (%) 
Encainide 153 NP 75 to 200 4 (2.6) 70 (46) 4 (5.7) 
Ethmozine 125 600 600 to 1200 3 (2.4) 62 (50) 3 (4.8) 
Lorcainide 144 NP 200 to 400 1 (0.7) 63 (44) l(l.6) 
Mexiletine 352 400 300 to 1200 3 (0.9) 146 (41) 3 (2.0) 
Propafenone 108 450 450 to 900 5 (4.7) 43 (40) 4 (9.3) 
Tocainide 251 800 600 to 2400 4 (1.6) 107 (43) 4 (3.7) 
Total 1,133 20 (1.8) 491 (43) 19 (3.9) 
NP = not performed; other abbreviations as in Table 1, 
Induction of congestive heart faiiure. Antiarrhythmic 
drug-induced congestive heart failure was defined as the 
emergence of appropriate symptoms (cough, shortness of 
breath, dyspnea on exertion, paroxysmal nocturnal dyspnea 
and reduced exercise tolerance) associated with either new 
radiologic findings consistent with congestive heart failure or 
the development of physical signs including pulmonary 
rales, S3 gallop sound and weight gain. So as to minimize the 
influence of other factors or progression of disease, a drug 
was implicated only if these findings developed within the 
first 2 weeks of therapy. Also, heart failure had to 1) be 
established by direct contact with and physical examination 
of the patient by one of the investigators, and 2) resolve 
completely after drug discontinuation or reduction of dose, 
3) appear in the absence of other causes of heart failure, such 
as new onset ischemia, dietary sodium indiscretion, use of 
other medications or intercurrent illness. 
Statistical analysis. Statistical analyses were performed 
by Student’s t test for paired values and by the chi-square 
analysis for categorical data. Significance was defined as a p 
value 50.05. Results are expressed as mean values ? SD. 
Results 
Incidence of drug-induced congestive heart failure (Table 
2). Congestive heart failure developed during 20 (1.8%) of 
the 1,133 antiarrhythmic drug trials. In 19 of these cases, the 
patient had a prior history of heart failure. Therefore, 
congestive failure was aggravated in 19 (3.8%) of 491 drug 
studies performed in patients with and in only 1 (0.16%) of 
the 642 tests in patients without congestive failure (p < .OOl). 
Thus, patients with a history of congestive heart failure have 
a nearly 24-fold greater risk of experiencing this adverse 
reaction than that of patients without prior cardiac decom- 
pensation. For any tested drug, the incidence rate of induc- 
tion of congestive heart failure was twice as high in those 
with as in those without a history of failure (range 1.6% with 
lorcainide to 9.3% with propafenone). 
Clinical characteristics of patients who developed heart 
failure (Table 3). The 20 episodes of new or worsened 
congestive heart failure involved 16 patients, or 3.9% of the 
total study group. These patients underwent 63 drug studies 
(range 2 to 7 [mean 3.9]/patient). Thus, aggravation of heart 
failure in these 16 patients occurred in 20 (32%) of the 63 
drug trials. Exacerbation of congestive heart failure with one 
drug did not predict this complication with another drug. The 
only patient without a history of congestive heart failure who 
developed heart failure with an antiarrhythmic drug had 
severe coronary artery disease, two previous myocardial 
infarctions and a left ventricular ejection fraction of 30%. 
Each of the 16 patients who had drug-induced congestive 
heart failure was being treated with digoxin, 14 with diuretic 
Table 3. Clinical Characteristics of 16 Patients With Drug-Induced 
Congestive Heart Failure 
No. (%) 
No. (%) male 9 (56) 
No. (%) female 7 (44) 
Age (yr) 
Mean 62 
Range 46 to 76 
No. (%) with cardiac diagnoses 
CAD 6 (37) 
CDM 10 (63) (p i O.OOl)* 
No. (%) with presenting arrhythmias 
VF 2 (12) 
Sustained VT 7 (44) 
Nonsustained VT 7 (44) 
Other 0 
No. (%) with history of CHF 15 (94) (p < o.OOl)* 
LVEF (%) 20 k 8 (p < O.OOl)* 
No. of drug tests 63 
No. of tests inducing CHF 20 (32) 
No. of patients with CHF induction with one drug 12 
No. of patients with CHF induction with two drugs 4 
*Compared with the 391 patients who did not develop congestive heart 
failure on antiarrhythmic drug therapy. Abbreviations as in Table 1. 
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Table 4. Clinical Characteristics of 167 Patients With a History of with compared with 23 patients (6%) without exacerbation of 
Congestive Heart Failure congestive heart failure had cardiomyopathy (p < 0.001). 
Total 
No. 167 
No. (%) male 127 (77) 
No. (%) female 40 1’3) 
Age (yr) 61 
No. (%) with cardiac 
diagnoses 
CAD I I9 (71) 
CDM 23 (14) 
Valvular disease 15 (9) 
Other IO (6) 
No. (%) with presenting 
arrhythmias 
VF so (30) 
Sustained VT 69 (41) 
Nonsustained VT 40 (24) 
Other 8 (5) 
LVEF (s/r) (n = 109) 27 A I4 




Induced Induced p Value 
IS 152 
8 (53) II9 (80) NS 
7 (471 33 (22) 10.02 
62 61 NS 
5 (33) II4 (75) NS 
IO (67) I3 (9) <O.OOl 
0 (0) I5 (9) NS 
0 (0) 10 (7) NS 
? (13) 48 (311 NS 
6 (40) 63 (41) NS 
7 (47) 33 (?I) NS 
0 (0) 8 (7) NS 
I9 f 8 28 t I5 co.04 
Role of preexisting left ventricular dysfunction. Marked 
left ventricular dysfunction, defined as a left ventricular 
ejection fraction <35%, was present in 120 patients of whom 
15 (12.5%) had drug-induced congestive heart failure. In 
contrast, only 1 (0.9%) of 12 patients with an ejection 
fraction ~35% (mean 37%) had this complication (p < 
0.001). Those who developed congestive heart failure did not 
differ significantly with respect to age, presenting arrhyth- 
mia, renal or liver function or dose of antiarrhythmic drug 
administered from other patients with a history of congestive 
heart failure (Table 4). However, the group that developed 
heart failure had a lower ejection fraction (19 2 8% versus 
27 ? 15%. p < 0.04) and a greater prevalence of cardiomy- 
opathy (67% versus 9%, p < 0.001) and included more 
women (47% versus 22%, p < 0.02). 
Discussion 
This study documents that each of six of the newer 
antiarrhythmic drugs has the potential to aggravate conges- 
tive heart failure. The overall incidence rate of this compli- 
cation was low (1.8%). However, when these drugs were 
administered to patients with a history of heart failure the 
incidence rate doubled (3.8%). Similar findings had been 
reported with disopyramide; this complication was noted in 
5% of patients without a history of failure in contrast to 55% 
among those who had experienced heart failure (1 I). 
drugs and 6 with vasodilators. At the time of drug testing, all 
16 patients were in sinus rhythm, 9 had an underlying 
conduction delay and 6 had left ventricular hypertrophy; all 
6 patients with coronary artery disease had Q waves consis- 
tent with old myocardial infarction. In 3 of the 16 patients, 
pulmonary edema developed within the first 24 h after 
administration of the new antiarrhythmic drug. The left- 
sided congestion resolved with diuretic therapy. In 12 pa- 
tients, congestive heart failure developed gradually over 2 to 
14 days after initiation of drug therapy and resolved com- 
pletely when the dose was decreased or the agent discontin- 
ued. One patient with a left ventricular ejection fraction of 
23% developed cardiogenic shock after 3 days of pro- 
pafenone administration at a dose of 900 mg/day. The patient 
needed intensive supportive care and recovered 3 days after 
the drug was discontinued. 
Patients in whom congestive failure was provoked (Table 
3) did not differ significantly from the study group as a whole 
(Table 1) with respect to age, gender, renal or liver function 
and presenting arrhythmia. There was no significant differ- 
ence in dose of the antiarrhythmic drug used. In each 
patient, the blood level was in the defined therapeutic range. 
Left ventricular ejection fraction in those who developed 
congestive heart failure was 20 t 8% compared with 39 2 
19% among the patients who did not. Although this differ- 
ence was significant (p < O.OOl), there was much overlap. A 
history of heart failure was present in 94% of those who 
developed congestive heart failure but in only 41% of those 
who did not develop failure (p < 0.001). Ten patients (63%) 
Predisposing factors. Our attempt to define features that 
would identify patients predisposed to antiarrhythmic drug- 
induced congestive failure was only partially successful. 
Although a history of congestive heart failure and preexist- 
ing significant left ventricular dysfunction were predisposing 
factors, the majority of patients with these clinical features 
tolerated the antiarrhythmic drugs without further decom- 
pensation. Thus, the provocation of congestive heart failure 
was unpredictable, even among these high risk patients. 
Patients were tested with several antiarrhythmic drugs; 
however. the negative inotropic effect caused by one drug 
did not predict such susceptibility with other agents, even 
those of a similar class. Other factors, such as the effect of 
the drug on peripheral vascular resistance, are also impor- 
tant and may account for differences among these agents. 
The significantly higher incidence of exacerbation of conges- 
tive heart failure among patients with cardiomyopathy is of 
some interest, but the number of the patients with cardio- 
myopathy was too small for this finding to be conclusive. 
The greater prevalence of women among those with wors- 
ening congestive heart failure may relate to a greater prev- 
alence of women among patients with cardiomyopathy, in 
contrast to their low prevalence among patients with coro- 
nary artery disease. 
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Reported incidence of drug-induced congestive heart fail- 
ure. The incidence of antiarrhythmic drug-induced conges- 
tive heart failure has been inadequately documented, espe- 
cially in patients with serious arrhythmias who have 
significant left ventricular dysfunction. Soyka (12) reviewed 
the experience with encainide in 1,245 patients enrolled in 
several comparative drug trials. Among the 386 patients with 
a history of congestive failure, possible encainide-induced 
worsening occurred in 13 (4.1%) in contrast to 7 (0.8%) 
among 859 patients without preexisting failure. Horn et al. 
(13) evaluated the safety of tocainide among 369 patients; 5 
(1.4%) experienced worsening of heart failure and all were in 
functional class IV. Reports (14-16) relating the hemody- 
namic effects of propafenone and mexiletine in patients with 
left ventricular dysfunction are limited to small numbers of 
patients, but the conclusions are not dissimilar to the find- 
ings of the present study. 
Limitations of the study. Our findings are subject to 
limitations inherent in any retrospective study design. The 
patient group is variable and there is a possibility of bias in 
drug selection for individual patients. However, as seen in 
Table 2, the percent of patients with a history of congestive 
failure undergoing testing with each drug was similar to the 
percent of patients with a history of congestive heart failure 
in the study group as a whole, suggesting that drug selection 
was not affected by clinical bias. Each patient who devel- 
oped congestive heart failure was seen by one of the physi- 
cians associated with the cardiovascular laboratory and, in 
each case, resolution of congestive heart failure after drug 
discontinuation was confirmed by reexamination. 
A small number of drug trials involved only short-term 
drug therapy. It is, therefore, possible that the incidence of 
congestive failure would have been higher had therapy been 
extended for longer periods of time. Also, we defined 
drug-induced congestive heart failure as that which occurred 
within 2 weeks of initiating therapy. The duration of drug 
exposure for expression of a negative inotropic effect is 
unknown and probably variable. Therefore, in some pa- 
tients, a longer period of drug administration may have been 
required to precipitate congestive failure. This would be 
especially true for those drugs that have active metabolites 
or that require a prolonged period of dosing before therapeu- 
tic blood levels are achieved. However, extending the period 
of observation would introduce numerous confounding fac- 
tors, thereby reducing the certainty of the role of antiar- 
rhythmic drugs in inducing congestive heart failure. 
Conclusions and clinical implications. Antiarrhythmic 
drugs possess negative inotropic effects and peripheral vas- 
cular actions that can aggravate or precipitate congestive 
heart failure. This complication appears to be more common 
in patients with significantly impaired left ventricular func- 
tion, a history of congestive heart failure or cardiomyopathy, 
but the incidence is low and unpredictable, even among 
patients at risk. Congestive heart failure is reversible when 
the drug is discontinued or the dose reduced. Although 
careful monitoring is advised when these antiarrhythmic 
drugs are administered to patients with reduced left ventric- 
ular ejection fraction and a history of congestive heart 
failure, they are not contraindicated, even in these high risk 
patients. 
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